Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ziopharm Oncology IN (ZIOP)

Ziopharm Oncology IN (ZIOP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 830,928
  • Shares Outstanding, K 181,030
  • Annual Sales, $ 150 K
  • Annual Income, $ -53,120 K
  • 60-Month Beta 2.60
  • Price/Sales 5,678.89
  • Price/Cash Flow N/A
  • Price/Book 7.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.96 +14.77%
on 11/08/19
4.79 -5.11%
on 11/20/19
+0.20 (+4.72%)
since 10/22/19
3-Month
3.72 +22.01%
on 10/17/19
5.65 -19.56%
on 08/23/19
-1.05 (-18.84%)
since 08/22/19
52-Week
1.56 +191.35%
on 12/27/18
7.25 -37.31%
on 07/31/19
+1.24 (+37.31%)
since 11/21/18

Most Recent Stories

More News
Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019 London Healthcare Conference

Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that the Company's presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019, has been moved to 1:20 p.m. GMT (8:20 a.m....

ZIOP : 4.56 (-0.65%)
Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast

Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Jefferies 2019 London Healthcare...

ZIOP : 4.56 (-0.65%)
Ziopharm: 3Q Earnings Snapshot

BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $74 million in its third quarter.

ZIOP : 4.56 (-0.65%)
Ziopharm Oncology Reports Third Quarter 2019 Financial Results

- Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) -

ZIOP : 4.56 (-0.65%)
Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019

Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7, at 4:30 p.m. ET to provide a corporate update and discuss financial...

ZIOP : 4.56 (-0.65%)
Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program

- Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots -

ZIOP : 4.56 (-0.65%)
Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors

- Industry veteran with 20+ years of global oncology drug development leadership -

ZIOP : 4.56 (-0.65%)
Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment

Jazz (JAZZ) enrolls first patient in a mid-stage study to evaluate defibrotide in prevention of neurotoxicity in relapsed/refractory DLBCL patients receiving CAR T-cell therapy.

BLUE : 71.62 (-2.80%)
ZIOP : 4.56 (-0.65%)
GILD : 65.30 (-0.65%)
JAZZ : 145.87 (+2.27%)
Patients Turn to Assistance Programs for Aid in the Fight Against Chronic Diseases

With the advancement of the cancer therapy market, new forms of treatment are now being studied and manufactured. Additionally, demand is expected to keep growing for currently effective treatments. Not...

CRIS : 1.65 (+1.21%)
IMMU : 18.48 (+0.43%)
ZIOP : 4.56 (-0.65%)
ONPH : 0.0250 (unch)
Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T

- Phase 1 clinical trial of CAR-T produced and infused in two days or less from gene transfer using Ziopharm's Sleeping Beauty platform -

ZIOP : 4.56 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The current trending strength of the market is Minimum.

See More Share

Trade ZIOP with:

Business Summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and...

See More

Key Turning Points

2nd Resistance Point 4.70
1st Resistance Point 4.64
Last Price 4.56
1st Support Level 4.53
2nd Support Level 4.48

See More

52-Week High 7.25
Fibonacci 61.8% 5.08
Last Price 4.56
Fibonacci 50% 4.40
Fibonacci 38.2% 3.73
52-Week Low 1.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar